Conference on 5th Annual Pain Management
The development of innovative therapeutics and complimentary technologies for the effective management of pain
 7th – 8th October 2008, BSG Conference Centre, London, UK

Dr Emanuele Sher, Research Advisor, Pain Migraine Team Leader, Eli Lilly & Co
Dr Mark Field, Global Research & Development, Pfi zer
Dr Adnan Al-Kaisy, Senior Physician, Pain Management Clinic London
Professor Peter McNaughton, Professor of Pharmacology, University of Cambridge
Professor Praveen Anand, Professor of Clinical Neurology, Imperial College London
Dr Dic Williams, Research Fellow, Pain Therapeutics, Pfi zer
Dr John Connell, Leader in Clinical Pharmacodynamics & Project Manager, Icon Development Solutions
Professor Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester
Professor Anthony Dickenson, Specialist in Pain Mechanisms, Professor of Neuro-Pharmacology, UCL
Professor Martin Koltzenburg, Professor Neuro-Physiology, UCL
 

This expected growth rate of 6.5% can be realised by addressing innovation within the industry - where drug-discovery can be developed through the utilisation of novel methods in drug-applications for the management of pain. Speciality Pharma business-models have arisen to catalyse this growth and recent breakthroughs by several companies within the sector, specifi cally through clinical trials, refl ect the realisation of this potential.

The next stage for such companies will be to capture niche markets in pain management in order to develop their portfolio of products which include a combination of formulated active entities working through either conventional routes of administration e.g. orally, or in conjunction with novel or improved drug-delivery technologies.

This, Visiongain’s 5th Annual Pain Management conference will create the appropriate environment for an exchange of ideas at mainly the corporate level, whilst also raising the awareness of potentially novel scientific developments in pain research, in a drive towards the next generation of pain management products in a market that is growing rapidly.

To gain a current and focused overview of the pain management industry that exists today

To assess and forecast the future of innovation in the pain- management industry To develop an up-to-date understanding of the product management framework created by Speciality Pharma business-models To explore integrated business-network solutions in order to troubleshoot Pharma pipeline projects associated with pain- management

To determine the viability of current research into revealing the mechanisms of pain and the potential this could have on novel drug development and drug-delivery technologies

To evaluate other more unconventional and/or controversial methods in pain-management

To create a suitable networking environment for the appropriate senior business developers and scientifi c leaders in the industry - in order to facilitate an exchange of ideas and an integration in approaches to pain-management deliverables

I look forward to meeting you at this conference,

Best regards,

Toby Roy
Conference Producer
Pharmaceutical Division

CEOs, Directors, Senior Business Developers, Senior Scientific Officers,

Senior Therapeutics and Pain Management Leaders, and Consultants from:

• Pharmaceutical and Biotechnology companies
• The Speciality Pharma industry
• Drug-delivery technology companies
• The Generic-based Pharma/Biotech industry
• Contract Research Organisations
• Regulatory Bodies
• Outsourcing-based organisations: Manufacturing and Equipment based
• Investment and Finance-based companies
• Marketing-based organisations

Day 1 -  5th Annual Pain Management Conference
Tuesday 7th October 2008

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 A review of patient care with respect to the administration of drugs and technologies for the management of pain

• An overview of current methods of administration
• Advantages and disadvantages of everyday patient care in pain management
• The future of patient care through pain management

Dr Adnan Al-KaisyConsultant in Pain Medicine & AnaesthesiaSt Thomas Hospital

10:50 Accelerating the development of analgesics through the use of biomarkers in early clinical development

• What can studies in healthy volunteers tell us about putative analgesic efficacy?
• Utility of pharmacodynamic models for acute pain, chronic pain and inflammation
• Challenge of validation and benchmarking of pain biomarkers
• Cost and time savings to drug development programmes by appropriate application of biomarkers

Dr John ConnellSenior Director, Scientific and Clinical OperationsIcon Development Solutions
11:30 Morning refreshments
11:50 Translational Research in Pain

Dr Mark FieldGlobal Research & DevelopmentPfizer
12:30 Presentation to be announced
13:10 Networking lunch

14:30 Speciality pharma business models – review, adapt, and grow

• An exploration of niche markets
• The incorporation and development of portfolios
• The principles of licensing
• Realising the potential of drug-delivery and collaboration with the generics industry

15:10 Dual Opioid Technology

• Immediate release Q8003IR
• Controlled release Q8011CR
• Licensing opportunities with Europe and the rest of the world

RepresentativeORx Pharmaceutical Corporation*

15:50 Afternoon refreshments

16:10 Panel Discussion: Innovation in pain management

• Why is there a lack of innovation in the pain management market?
• New revelations in research into pain mechanisms
• The potential impact of pre-clinical research on the future of drug development for the management of pain
• Technology designed to improve the delivery of drugs

17:15 Networking Drinks Reception

Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2 - 5th Annual Pain Management Conference
Wednesday 8th October 2008

09:30 Registration and refreshments
10:00 Opening address from the chair
Dr Emanuele SherResearch Advisor, Pain Migraine/Team LeaderEli Lilly & Co
10:10 Why pain gets worse

• The activation of TRP channels
• The importance of heat hyperalgesia and inflammatory mediators
• The role of membrane P1P2, protein kinases PKA and PKC, and phosphates
• The AKAP79/150 and TRPV1 scaffold – a potential target

Professor Peter McNaughtonProfessor of PharmacologyUniversity of Cambridge, Department of Pharmacology

10:50 Clinical translational models for chronic pain states

• Clinical models for biomarkers for TRPs, Na channels and CNS Microglia
• In vitro human models for inflammatory and chemotherapy-induced neuropathic pain
• Novel drug-target validation in clinical and in vitro pain models
• Clinical "Pain Genes" as models for novel Drug Development

Professor Praveen AnandProfessor of Clinical NeurologyImperial College London

11:30 Morning refreshments

11:50 Risk benefits of nicotinic receptor modulation for pain management

• Neuronal acetylcholine nicotinic receptors and the modulation of various CNS pathways - relevance to nociception
• Developing subtype-selective nicotinic receptor agonists AND maintaining efficacy in directed pain treatment WHILST reducing peripheral side effects
• Selective neuronal nicotinic receptor agonists gaining market approval for non-pain management uses
• The drive for new receptor targeted nicotinic pain therapeutics

Dr Emanuele SherSenior Research Advisor, Discovery NeurosciencePain Migraine Drug hunting Team, Eli Lilly & Co.

12:30 Using imagery for pain management

• Examining the use of specific imagery techniques for managing a variety of chronic pain issues
• Reviewing common imagery themes
• Providing an overview of effective induction techniques
• Discussing applications of imagery strategies
• Identifying techniques for use with non-visual patients

Professor Anthony Jones
Professor of Neuro-Rheumatology
University of Manchester, School of Medicine*

13:10 Networking lunch

14:30 Understanding the mechanisms of pain
• The various definitions of pain
• The different pain-states
• An overview of the forms of treatment
• Current approaches to managing pain
• Future developments in pain management Professor Anthony Dickenson

Specialist in Pain Mechanisms, University College London

Professor of Neuropharmacology, Department of Pharmacology

15:10 Neurophysiological biomarkers for the investigation of target engagement in the peripheral and central nervous system
 • Assessment of peripheral nociceptors function
 • Nerve excitability testing for the study of voltage gated ion channels
• Transcranial magnetic stimulation to investigate cortical excitability
 • Nociceptive reflex studies of pain and analgesia Professor Martin Koltzenburg

Professor of Clinical Neurophysiology, Head of department of Neurophysiology
UCL

15:50 Afternoon refreshments

16:10 Pregablin and fibromyalgia: mechanistic considerations Dr Dic Williams
Research Fellow, Pain Therapeutics
Pfizer

16:50 Presentation to be announced
17:30 Chair’s closing remarks and end of conference
 

Fee Per Delegate

 

Conference only

£1526.33

Click here to order